Technological strategies for amphotericin B formulations in lipid systems available in the pharmaceutical market and other promising delivery systems

Abstract

Amphotericin B (AmB) is an antifungal reference drug in treatment of systemic mycoses since its discovery in the years 1950. The aim of this study was to establish the state of the art of the technological strategies involved in the
administration drug dosage forms AmB and the the paths for intervention to improve the drug solubility, allowing its administration intravenously and minimize its toxicity. The importance of the studies to the medical-pharmaceutical field is related to new drug delivery systems that can increase membership by children and the elderly, in addition to increasing the therapeutic arsenal available to the medical clinic. Due the limited clinical utility of the normal AmB formulations because of its high toxicity, the new administration systems of AmB able to direct the antibiotic directly to site of infections has been the most studied. Therefore, the need for different vehicles other than the deoxycholate (Fungizon ®) has been the most common alternative. The lipid formulations have been shown to be more effective and less toxic when compared to AmB deoxycholate, but not yet introduced to hospital routine for treating deep mycoses.